NYU Langone Cardiologists Showcase Groundbreaking Research at AHA 2025 Sessions

Groundbreaking Research at AHA Scientific Sessions 2025

The Leon H. Charney Division of Cardiology at NYU Langone Health is excited to present its innovative research at the American Heart Association's Scientific Sessions 2025, taking place from November 7 to 10 in New Orleans. This annual gathering showcases pivotal studies that are set to transform how heart disease is understood and treated.

During this prestigious event, cardio-experts from NYU Langone will highlight significant areas of research, including the role of inflammation in heart disease, specific heart attack types that predominantly affect women, and the interactions between kidney function and heart failure management, among others. Their findings not only contribute substantially to the global knowledge pool but also aim to enhance the quality of care provided to patients.

Among the highlighted presentations, Dr. Judith S. Hochman, a revered figure in cardiology and senior associate dean for clinical sciences at NYU Langone, has been recognized with the 2025 Research Achievement Award. This accolade, presented on November 9, acknowledges her unwavering commitment to advancing cardiovascular research and improving patient outcomes over her lengthy career. Dr. Hochman's influential work in understanding myocardial infarction has left an indelible mark on the field.

One of the key studies presented at the conference explores risk factors associated with heart dysfunction in patients receiving Mavacamten, an FDA-approved treatment for obstructive hypertrophic cardiomyopathy. Led by Dr. Daniele Massera, this research identified specific patient factors, such as left bundle branch block or atrial fibrillation, that heighten the risk of left ventricular systolic dysfunction. By focusing on these aspects, the study seeks to tailor treatment strategies that would optimize patient care and outcomes in the long run.

Another significant presentation focuses on MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries), a type of heart attack occurring mainly in women. Dr. Harmony R. Reynolds sheds light on this complex condition, discussing its diagnosis and treatment pathways that reflect the unique physiological characteristics of affected patients.

Meanwhile, Dr. Carine Hamo presents a compelling abstract on the interplay between kidney health and heart failure management. It's noted that while a decline in kidney function is common following the initiation of most heart failure therapies, these changes do not inherently lead to poor outcomes. This new insight emphasizes the need for a balanced approach, ensuring that heart failure therapies continue uninterrupted to preserve their benefits.

In addition to these presentations, NYU Langone will also highlight other research, such as the recent trial comparing Ticagrelor to Prasugrel in patients with diabetes and multivessel coronary artery disease, giving participants valuable insights into effective treatment options.

The research showcased at the AHA Scientific Sessions signifies NYU Langone Heart's status as a frontrunner in cardiology. Ranked as the best in the nation for cardiology and vascular surgery by U.S. News & World Report, NYU Langone Heart is dedicated to providing exemplary patient care and pioneering research designed to address pressing health challenges.

Dr. Hochman reflects on her honor, crediting her collaborative community of researchers and the meaningful impact they strive to make in improving cardiovascular health outcomes. The work presented at AHA 2025 furthers this dialogue, fostering advancements in patient care rooted in rigorous research and dedication to the field.

As the event unfolds, participants and attendees are encouraged to engage with the latest findings, contributing to a broader understanding of heart health and the future of cardiovascular treatments.